Abstract
The soluble epoxide hydrolase mRNA level in liver was increased eight-fold upon administration of the hypolipidemic drug and peroxisome proliferator clofibrate for 7 days to mice. The soluble epoxide hydrolase mRNA was back at control levels within 1-2 days after clofibrate withdrawal. The highest expression was in liver, intestine and kidney. Lower levels were found in heart and muscle and very low levels were found in testes, lung, brain and spleen. The mRNA levels were increased in liver, kidney and heart by clofibrate.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animal Feed / toxicity
-
Animals
-
Blotting, Northern
-
Clofibrate / toxicity*
-
Epoxide Hydrolases / biosynthesis*
-
Epoxide Hydrolases / drug effects
-
Epoxide Hydrolases / genetics
-
Intestines / drug effects*
-
Intestines / enzymology
-
Kidney / drug effects*
-
Kidney / enzymology
-
Liver / drug effects*
-
Liver / enzymology
-
Male
-
Mice
-
Molecular Sequence Data
-
Organ Specificity / drug effects*
-
Organ Specificity / genetics
-
RNA, Messenger / drug effects*
-
Solubility
Substances
-
RNA, Messenger
-
Epoxide Hydrolases
-
Clofibrate